Rodney P. Rocconi, MD | Authors


An Overview of Vigil Personalized Engineered Autologous Tumor Cells in Ovarian Cancer

March 27, 2018

Rodney P. Rocconi, MD, chief of Gynecologic Oncology Service, associate director for Clinical Research, professor of Interdisciplinary Clinical Oncology, discusses a phase I trial of Vigil personalized engineered autologous tumor cells in ovarian cancer during the 2018 Society of Gynecologic Oncology Annual Meeting.